Zent, C. S., Taylor, R. P., Lindorfer, M. A., Beum, P. V., LaPlant, B., Wu, W., . . . Witzig, T. E. (2014). Chemoimmunotherapy for Relapsed/Refractory and Progressive 17p13 Deleted Chronic Lymphocytic Leukemia (CLL) Combining Pentostatin, Alemtuzumab, and Low Dose Rituximab is Effective and Tolerable and Limits Loss of CD20 Expression by Circulating CLL Cells. Am J Hematol.
Chicago ZitierstilZent, Clive S., et al. "Chemoimmunotherapy for Relapsed/Refractory and Progressive 17p13 Deleted Chronic Lymphocytic Leukemia (CLL) Combining Pentostatin, Alemtuzumab, and Low Dose Rituximab Is Effective and Tolerable and Limits Loss of CD20 Expression By Circulating CLL Cells." Am J Hematol 2014.
MLA ZitierstilZent, Clive S., et al. "Chemoimmunotherapy for Relapsed/Refractory and Progressive 17p13 Deleted Chronic Lymphocytic Leukemia (CLL) Combining Pentostatin, Alemtuzumab, and Low Dose Rituximab Is Effective and Tolerable and Limits Loss of CD20 Expression By Circulating CLL Cells." Am J Hematol 2014.